Market Intel: Emerging Markets Are Fertile Frontier For CRM Device-Makers
The global cardiac rhythm management market is set to grow at a compound annual growth rate of 4.8% to about $13.5bn by 2021. This article, based on findings from a Meddevicetracker report, provides an in-depth look at where the growth markets are, the evolving competitive landscape, and discusses the key players and upcoming technological trends that will bolster this market.
You may also be interested in...
The firm’s Assurity MRI pacemaker and Tendril MRI pacing lead, acquired in its recent St. Jude Medical deal, gained US FDA approval after some delay. Lack of this designation has been a competitive challenge for the business in the past year.
Abbott Laboratories has finalized its $25b takeover of St. Jude Medical, first announced in April, making Abbott a major player in almost every corner of the $30bn cardiovascular device market.
The US FDA has approved Boston Scientific's next-generation Emblem S-ICD subcutaneous implantable defibrillator earlier than expected with plans to launch in the US by this fall. The firm has also CE marked the device in Europe.